Detail page

Knowledge Web

Person

Julian Baumeister (1987-)

Biologe

Name	Julian Baumeister
Time	1987- (Date of birth and death)
Place	Haan (Geburtsort) Deutschland
Academic degree	Dr. rer. nat.
Profession	Biologe (characteristic profession)
Variant	J. Baumeister
Further information	Dissertation an der Rheinisch-Westfälischen Technischen Hochschule Aachen, Fakultät für Mathematik, Informatik und Naturwissenschaften, 2020.
Source	Dissertation
Record type	Person
GND-Identifier	1212972201
Record ID	1212972201
Involved in show all Designing and modeling nanomedicines towards image-guided drug delivery in hematological malignancies Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms Engineering Mesoscopic 3D Tumor Models with a Self‐Organizing Vascularized Matrix (Adv. Mater. 5/2024) Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms Engineering Mesoscopic 3D Tumor Models with a Self‐Organizing Vascularized Matrix Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms Engineering Mesoscopic 3D Tumor Models with a Self-Organizing Vascularized Matrix Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN Dissecting the role of hypoxia-inducible factor 1 (HIF-1) in JAK2V617F-positive myeloproliferative neoplasms (MPN) Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation Nrf2 Is a Central Regulator of Metabolic Reprogramming of Myeloid-Derived Suppressor Cells in Steady State and Sepsis

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Julian Baumeister (1987-)

Designing and modeling nanomedicines towards image-guided drug delivery in hematological malignancies

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms

Engineering Mesoscopic 3D Tumor Models with a Self‐Organizing Vascularized Matrix (Adv. Mater. 5/2024)

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms

Engineering Mesoscopic 3D Tumor Models with a Self‐Organizing Vascularized Matrix

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms

Engineering Mesoscopic 3D Tumor Models with a Self-Organizing Vascularized Matrix

Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms

Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms

Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms

Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition

Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells

CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes

Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN

Dissecting the role of hypoxia-inducible factor 1 (HIF-1) in JAK2V617F-positive myeloproliferative neoplasms (MPN)

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Nrf2 Is a Central Regulator of Metabolic Reprogramming of Myeloid-Derived Suppressor Cells in Steady State and Sepsis